Brian Posner Buys 2,500 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner purchased 2,500 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average price of $17.48 per share, with a total value of $43,700.00. Following the transaction, the director owned 22,500 shares of the company’s stock, valued at approximately $393,300. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Dyne Therapeutics Trading Down 7.4%

Shares of DYN stock opened at $17.04 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The stock has a market cap of $2.82 billion, a P/E ratio of -5.29 and a beta of 1.09. The business has a fifty day simple moving average of $18.28 and a 200-day simple moving average of $18.28. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the previous year, the firm posted ($1.05) earnings per share. On average, analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DYN has been the subject of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research report on Friday, May 15th. HC Wainwright cut their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DYN. AQR Capital Management LLC acquired a new position in shares of Dyne Therapeutics during the 1st quarter worth approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after acquiring an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after acquiring an additional 366,183 shares during the last quarter. Caxton Associates LLP acquired a new position in Dyne Therapeutics in the 1st quarter valued at $157,000. Finally, Creative Planning raised its holdings in Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after acquiring an additional 2,797 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.